A Double-blind, Randomized, Placebo-controlled Phase 1 Study in Healthy Male Adults to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Dose of ABT-333.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2010
At a glance
- Drugs Dasabuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Abbott Laboratories
- 12 Aug 2009 Actual number of patients (39) and actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 12 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.